PNV 4.12% $2.56 polynovo limited

Ann: PolyNovo Awarded BARDA Contract for Burns Trial, page-2

  1. 5,260 Posts.
    lightbulb Created with Sketch. 242
    Initial phase value of contract is US$8.2 million for 10 patient clinical trial, which if showing successful outcomes may be followed at BARDA’s discretion by a US$18 million 150 patient trial, which if successful will lead to a fully funded PMA pathway to FDA approval valued at a further US$26 Million. Total potential value: US$52.2 million over perhaps 3-4 years. Not bad.
    Last edited by jevalent: 29/09/15
 
watchlist Created with Sketch. Add PNV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.